MSK’s History of Discoveries To Prevent Breast Cancer Resistance: In , the laboratory of Sarat Chandarlapaty, MD, PhD, discovered how mutations in the ESR1 gene cause resistance to hormone therapy, which led to FDA approval in of a drug, elacestrant (Orserdu™) for certain patients.